Search
Ripasudil
go.drugbank.com/drugs/DB13165InvestigationalIt was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.
Categories: Sympathomimetics in Glaucoma TherapyOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.
Influenza A virus A/Singapore/GP1908/2015 IVR-180 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14462ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot 2018-2019Influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14463ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot 2018-2019MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.). … MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM.
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468] … [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections
Resmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigational[L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD
Imelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigationalImelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine. … [L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922]
Aceclidine
go.drugbank.com/drugs/DB13262ApprovedAceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]